On Friday, BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s shares declined -4.06% to $6.61.
BioDelivery Sciences International, Inc. (BDSI) declared the approval by the U.S. Food and Drug Administration (FDA) of a Supplemental New Drug Application (sNDA) for a new formulation of ONSOLIS® (fentanyl buccal soluble film) CII for the administration of breakthrough pain in patients with cancer who are opioid tolerant. The new formulation was presented to address formerly declared appearance-related changes.
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain administration and addiction. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which comprises of a small, bi-layered erodible polymer film for application to the buccal mucosa.
Incyte Corporation (NASDAQ:INCY)’s shares dropped -1.96% to $105.80.
Incyte Corporation (INCY) stated 2015 second-quarter financial results, counting revenue from Jakafi.
The Company highlighted the continued momentum in the commercialization of Jakafi in the U.S., in addition to progress being made across its clinical portfolio, counting the results of two pivotal trials of baricitinib that were presented with Eli Lilly and Company (“Lilly”) at the 2015 European League Against Rheumatism (EULAR) meeting in June. In addition, positive proof-of-concept results from the novel:novel combination of Incyte’s PI3Kδ inhibitor INCB40093 and JAK1-selective inhibitor INCB39110 in B-cell malignancies were presented at both the 2015 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings in the second quarter of 2015.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line comprises ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, in addition to INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer.
At the end of Friday’s trade, American Tower Corp (NYSE:AMT)‘s shares surged 0.87% to $101.08.
American Tower Corporation (AMT) stated financial results for the quarter ended June 30, 2015.
SECOND QUARTER 2015 OPERATING RESULTS OVERVIEW
American Tower generated the following operating results for the quarter ended June 30, 2015 (unless otherwise indicated, all comparative information is presented against the quarter ended June 30, 2014).
Total revenue raised 13.9% to $1,174 million, and total rental and administration revenue raised 14.8% to $1,154 million.
Total rental and administration revenue Core Growth was about 23.2%, and total rental and administration Organic Core Growth was about 7.3%.
Total rental and administration Gross Margin raised 13.1% to $843 million, and total rental and administration Gross Margin percentage was 73%.
Adjusted EBITDA raised 11.7% to $762 million, Core Growth in Adjusted EBITDA was 21.1%, and Adjusted EBITDA Margin was 65%.
American Tower Corporation is a real estate investment trust. It invests in the real estate markets across the globe. The firm engages in leasing of space on multi-tenant communications sites to wireless service providers, radio and television broadcast companies, wireless data and data providers, government agencies and municipalities and tenants in a number of other industries. American Tower Corporation was founded in 1995 and is headquartered in Boston, Massachusetts.
Assured Guaranty Ltd. (NYSE:AGO), ended its Friday’s trading session with 1.32% gain, and closed at $26.66.
In a June 29 rating report on Assured Guaranty Ltd. (AGO) and its operating auxiliaries (collectively, Assured Guaranty), Standard & Poor’s Ratings Services (S&P) affirmed the AA Stable Outlook financial strength ratings of U.S. bond insurers Assured Guaranty Municipal Corp.
Assured Guaranty Ltd., through its auxiliaries, provides credit protection products to public finance, infrastructure, and structured finance markets in the United States and internationally. It offers financial guaranty insurance that protects holders of debt instruments and other monetary obligations from defaults in planned payments. The company insures various debt obligations, counting bonds issued by the United States state or municipal governmental authorities; notes issued to finance infrastructure projects; and asset-backed securities issued by special purpose entities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
